Mykare's new funding round fuels AI enhancements for its hospital operating system, aiming to streamline patient journeys across international markets.
Mykare closed a $3.2 million bridge round on June 29, 2026, adding $1 million from Papa.com co‑founders Andrew Parker and Alfredo Vaamonde and a Middle‑Eastern family office. The cash will fund AI upgrades, faster product cycles and deeper market penetration, co‑founder Senu Sam told Inc42.
Founded in 2022, Mykare began as a B2C platform linking patients to affordable hospital networks. By October 2025 it pivoted to a B2B model, offering an AI‑native healthcare operating system (OS) to small‑ and medium‑sized hospitals. The OS claims to automate the entire patient journey—acquisition, appointment booking, follow‑up, feedback collection and CRM synchronization—through a suite of voice‑enabled agents.
The newly raised capital builds on a 2023 seed round that netted $2.2 million from OnDeck ODX, Avaana Seed and others. Mykare says its agents can parse patient intent, answer calls, schedule visits, trigger reminders and push data into existing practice management tools without human intervention. In practice, a clinic could field a call, confirm insurance eligibility and lock in a slot within seconds, freeing staff for higher‑value care.
Artificial intelligence in medicine is moving from decision‑support to operational automation, and Mykare positions itself at the front of that shift. While large models like OpenAI’s GPT‑5.6 are under government scrutiny for safety, Mykare’s focus is narrower: domain‑specific language models trained on appointment‑flow data. The company argues this specialization reduces hallucination risk and compliance overhead, a claim that resonates with regulators increasingly wary of generic AI deployments.
Industry observers note that Mykare’s timing aligns with a broader surge in AI‑driven health‑tech funding. Forbes recently highlighted how ChatGPT’s 800 million monthly users have spurred venture capital into niche AI applications, from coding assistants to patient triage bots. Mykare’s bridge round, though modest compared with multi‑billion‑dollar AI valuations, signals confidence that a focused, hospital‑level AI stack can generate measurable ROI for providers.
The startup’s roadmap includes rolling out a multilingual voice interface for its existing markets in Southeast Asia and the Middle East, and piloting a predictive analytics module that flags high‑risk patients based on appointment history. If successful, the module could feed directly into electronic health records, enabling proactive outreach before a condition escalates.
Critics caution that automation of front‑desk tasks may erode patient‑staff relationships, especially in cultures where personal interaction is valued. Mykare counters that its agents are designed to hand off to human operators when sentiment analysis detects frustration, preserving the human touch while still cutting routine workload.
The bridge round also reflects a strategic partnership angle. Papa.com’s founders, who built a home‑care platform powered by AI, bring operational expertise and a network of potential hospital clients. Their involvement may accelerate Mykare’s entry into North American markets, where regulatory hurdles are higher but reimbursement models for tele‑health and AI services are more mature.
Overall, Mykare’s funding underscores a maturing segment of health‑tech where AI is less about breakthrough research and more about incremental efficiency gains. As hospitals grapple with staffing shortages and rising administrative costs, a reliable AI OS that can handle the minutiae of patient flow could become a competitive differentiator.
The next test will be scalability. Mykare must prove that its agents can maintain accuracy across diverse languages, dialects and health‑system workflows without a spike in errors. Success would validate the hypothesis that narrow, purpose‑built AI can outpace general‑purpose models in regulated environments.
Will Mykare’s AI OS become the de‑facto middleware for midsize hospitals, or will it be eclipsed by larger platforms that bundle clinical decision support with operational tools? The answer will hinge on adoption rates, integration depth and the ability to demonstrate cost savings that outweigh implementation friction.
FAQ
What exactly does Mykare’s AI platform automate?
It handles patient intake, voice‑based appointment scheduling, follow‑up reminders, feedback collection and automatic CRM updates.
How much funding has Mykare raised to date?
The company closed a $3.2 million bridge round in June 2026, on top of a $2.2 million seed round in 2023.
Is Mykare’s technology compliant with health data regulations?
Mykare states that its models are trained on de‑identified data and that it follows HIPAA and GDPR guidelines, but third‑party audits are pending.
Which markets is Mykare targeting next?
Beyond its current foothold in Southeast Asia and the Middle East, the startup aims to enter North America and Europe with multilingual voice agents and predictive analytics pilots.
